SCHEMBL9953589

SCHEMBL9953589

O=C(O)CCCCCC(=O)c1ccc(F)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.74
RAB9A P51151 1/20 0.74
HDAC3 O15379 1/20 0.69
HDAC4 P56524 1/20 0.69
HDAC1 Q13547 1/20 0.69
HDAC7 Q8WUI4 1/20 0.69
HDAC2 Q92769 1/20 0.69
HDAC10 Q969S8 1/20 0.69
HDAC11 Q96DB2 1/20 0.69
HDAC8 Q9BY41 1/20 0.69
HDAC6 Q9UBN7 1/20 0.69
HDAC9 Q9UKV0 1/20 0.69
HDAC5 Q9UQL6 1/20 0.69
HTR7 P34969 1/20 0.65
L3MBTL1 Q9Y468 3/20 0.59
LMNA P02545 1/20 0.59
MAPT P10636 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
PDE4B Q07343 1/20 0.54
PTPN1 P18031 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3866967 0.98 NPC1 (0.77) NPC1RAB9AHDAC3HDAC4HDAC1
SCHEMBL296337 0.94 NPC1 (0.84) NPC1RAB9AHDAC3HDAC4HDAC1
SCHEMBL1040636 0.92 NPC1 (0.87) NPC1RAB9AHDAC3HDAC4HDAC1
SCHEMBL3424496 0.92 NPC1 (0.87) NPC1RAB9AHDAC3HDAC4HDAC1
SCHEMBL9680984 0.92 NPC1 (0.87) NPC1RAB9AHDAC3HDAC4HDAC1
SCHEMBL9680520 0.90 NPC1 (0.91) NPC1RAB9AHTR7L3MBTL1LMNA
SCHEMBL315309 0.86 RAB9A (0.69) NPC1RAB9AHTR7L3MBTL1LMNA
SCHEMBL5253936 0.85 NPC1 (0.74) NPC1RAB9AHDAC3HDAC4HDAC1
SCHEMBL7392018 0.85 NPC1 (0.74) NPC1RAB9AHDAC1HDAC8HTR7
SCHEMBL5253938 0.85 NPC1 (0.74) NPC1RAB9AHDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2661265-B1 QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2017-03-08 EP disclosed
US-9290453-B2 Quinolines and aza-quinolines as CRTH2 receptor modulators MERCK SHARP & DOHME CORP. (US) 2016-03-22 US disclosed
EP-2661265-A1 QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS Merck Sharp & Dohme Corp. (US) 2013-11-13 EP disclosed
US-20130296300-A1 QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME LLC 2013-11-07 US disclosed
WO-2012087872-A1 QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296300-A1 QUINOLINES AND AZA-QUINOLINES AS CRTH2 RECEPTOR MODULATORS HRH2, NPY2R, CNKSR1 NPC1 2212/4885RAB9A 563/4885HDAC3 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.